New York State Common Retirement Fund Grows Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

New York State Common Retirement Fund raised its position in 10x Genomics, Inc. (NASDAQ:TXG) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 642,915 shares of the company’s stock after buying an additional 3,994 shares during the period. New York State Common Retirement Fund’s holdings in 10x Genomics were worth $35,978,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of 10x Genomics by 56.4% during the third quarter. FMR LLC now owns 12,666,998 shares of the company’s stock worth $522,514,000 after purchasing an additional 4,565,400 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of 10x Genomics by 35.0% during the fourth quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock worth $226,150,000 after purchasing an additional 1,047,827 shares in the last quarter. SVB Wealth LLC increased its stake in shares of 10x Genomics by 92.1% during the fourth quarter. SVB Wealth LLC now owns 1,446,552 shares of the company’s stock worth $80,949,000 after purchasing an additional 693,422 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of 10x Genomics by 32.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock worth $127,786,000 after purchasing an additional 565,059 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of 10x Genomics by 4.2% during the third quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company’s stock worth $367,270,000 after purchasing an additional 354,921 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 2,821 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $130,725.14. Following the sale, the chief executive officer now directly owns 847,560 shares of the company’s stock, valued at approximately $39,275,930.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Serge Saxonov sold 2,821 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $130,725.14. Following the sale, the chief executive officer now directly owns 847,560 shares of the company’s stock, valued at approximately $39,275,930.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 2,613 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the sale, the insider now directly owns 283,059 shares in the company, valued at $13,116,954.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,959 shares of company stock worth $592,806. 10.65% of the stock is currently owned by insiders.

10x Genomics Trading Down 2.3 %

NASDAQ:TXG opened at $26.90 on Friday. The company’s 50-day moving average is $38.12 and its two-hundred day moving average is $42.60. 10x Genomics, Inc. has a 1-year low of $26.30 and a 1-year high of $63.57.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The company had revenue of $183.98 million during the quarter, compared to analyst estimates of $182.73 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The business’s revenue was up 17.8% compared to the same quarter last year. Equities research analysts predict that 10x Genomics, Inc. will post -1.47 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on TXG shares. Stifel Nicolaus cut their target price on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Barclays lowered their price target on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, 10x Genomics has an average rating of “Moderate Buy” and a consensus price target of $60.22.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.